$1.11
-0.13 (-10.16%)
Open$1.24
Previous Close$1.23
Day High$1.25
Day Low$1.10
52W High$9.22
52W Low$0.91
Volume—
Avg Volume204.8K
Market Cap23.33M
P/E Ratio—
EPS$-0.99
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,947.1% upside
Current
$1.11
$1.11
Target
$22.62
$22.62
$15.82
$22.62 avg
$24.89
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 11.82M | 10.52M | 11.40M |
| Net Income | 3.06M | 2.28M | 2.66M |
| Profit Margin | 25.9% | 21.7% | 23.3% |
| EBITDA | 4.32M | 3.67M | 4.36M |
| Free Cash Flow | 3.21M | 3.03M | 2.01M |
| Rev Growth | +9.7% | +22.7% | +8.4% |
| Debt/Equity | 0.16 | 0.13 | 0.16 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |